RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:251627

Oligodendroglioma grade 2

high confidenceDisorder

Also known as: Oligodendroglioma

Publications

24,026

98.9th percentile

Trials

175

Interventional, condition-specific

Researchers

1,570

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare glial tumor characterized by a highly cellular lesion that is diffusly infiltrating at the periphery and consists of evenly-spaced monomorphic cells with the oligodendroglial . It typically occurs in the supratentorial white matter. Histologically, the cells are uniformly round to oval with round nuclei, delicate chromatin and small nucleoli. Most patients present with .

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

WHO grade II oligodendroglial neoplasm · WHO grade II oligodendroglial tumor · WHO grade II oligodendroglial tumour · oligodendroglioma · well differentiated oligodendroglial tumor · well differentiated oligodendroglial tumour · well differentiated oligodendroglioma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    24,026 matched papers (14,143 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    175 matched on ClinicalTrials.gov (22 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

24,026

24,026 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

24,026 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

14,143 in the last 10 years · high confidence · 98.9th percentile (publications denominator)

Phrase hits: 24,026 · MeSH hits: 519

Open Europe PMC search

Who's working on it?

1,570

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Brandal P4 papers · 2026

    Department of Oncology, Oslo University Hospital, Oslo, Norway.

    Papers in Europe PMC
  2. 02
    Jakola AS4 papers · 2026

    Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

    Papers in Europe PMC
  3. 03
    Miller JJ4 papers · 2026

    Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

    Papers in Europe PMC
  4. 04
    Abe O3 papers · 2026

    Department of Radiology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

    Papers in Europe PMC
  5. 05
    Blomstrand M3 papers · 2026

    Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

    Papers in Europe PMC
  6. 06
    Cahill DP3 papers · 2026

    Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

    Papers in Europe PMC
  7. 07
    De Vleeschouwer S3 papers · 2026

    Department of Neurosurgery, UZ Leuven, Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.

    Papers in Europe PMC
  8. 08
    Duffau H3 papers · 2026

    Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center , ,

    Papers in Europe PMC
  9. 09
    Henssen D3 papers · 2026

    Department of Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

    Papers in Europe PMC
  10. 10
    Herold-Mende C3 papers · 2026

    Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

175

interventional trials for this specific condition

175 interventional trials matched this specific condition name; 22 currently recruiting in our sample.

Data as of 27 July 2026

175 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.1th percentile).

high confidence · 99.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

175 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

26 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Oligodendroglioma grade 2" OR "Oligodendroglioma" OR "WHO grade II oligodendroglial neoplasm" OR "WHO grade II oligodendroglial tumor" OR "WHO grade II oligodendroglial tumour" OR "well differentiated oligodendroglial tumor" OR "well differentiated oligodendroglial tumour" OR "well differentiated oligodendroglioma"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Oligodendroglioma

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Oligodendroglioma grade 2" OR "Oligodendroglioma" OR "WHO grade II oligodendroglial neoplasm" OR "WHO grade II oligodendroglial tumor" OR "WHO grade II oligodendroglial tumour" OR "well differentiated oligodendroglial tumor" OR "well differentiated oligodendroglial tumour" OR "well differentiated oligodendroglioma"

Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 175 interventional · 26 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:50:28.169Z